Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05712161 · ClinicalTrials.gov registry record · NA

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

A NA study of Aortic Stenosis and Symptomatic Aortic Stenosis, sponsored by Anteris Technologies.

Active
Registry status
NA
Development phase
15
Enrollment target
5
Study locations

NCT05712161: Active NA study of Aortic Stenosis and Symptomatic Aortic Stenosis, sponsored by Anteris Technologies.

NCT05712161 is a NA study of Aortic Stenosis and Symptomatic Aortic Stenosis that is active but no longer recruiting, run by Anteris Technologies. The registered enrollment target is 15 participants, below the 1,362-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05712161, a NA study of Aortic Stenosis and Symptomatic Aortic Stenosis, is active but no longer recruiting, sponsored by Anteris Technologies.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
5
Study locations

Study Summary

To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.

Primary Outcome

Mortality would be reported as rate of death/mortality at 30 days. Disabling stroke would be reported according to VARC-3 Guidelines

Interventions

  • DEVICE DurAVRTM THV System

Study Locations (5)

New York

  • Columbia University Medical Center/NYPH - New York
  • Montefiore Medical Center - The Bronx

Arizona

  • Tucson Medical Center - Tucson

Michigan

  • University of Michigan - Ann Arbor

Ohio

  • Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-08-07
Est. Completion 2033-12
Phase NA
Anteris Technologies

2 total trials

What the registry record for NCT05712161 still lists

NCT05712161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,362-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which DurAVRTM THV System is the first listed.

NCT05712161 lists 5 locations in 4 states (New York, Arizona, Michigan).

Frequently Asked Questions

What is clinical trial NCT05712161 about?

NCT05712161 is a clinical study titled "Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study". To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.

What is the current status of trial NCT05712161?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-08-07. Estimated completion is 2033-12.

What conditions does trial NCT05712161 study?

This clinical trial studies the following conditions: Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Valve Calcification, Severe Aortic Valve Stenosis.

What interventions are being tested in trial NCT05712161?

The interventions under investigation include: DurAVRTM THV System (DEVICE).

Who is sponsoring clinical trial NCT05712161?

This trial is sponsored by Anteris Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05712161 being conducted?

This trial has 5 study locations across Arizona, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Stenosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05712161's enrollment target sits among peer trials

15 24th of 26 higher than 3 of 26 other Aortic Stenosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aortic Stenosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05712161, the US trial registry maintained by the National Library of Medicine. NCT05712161 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.